Aethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 13, 2026

This is a routine notice for an upcoming financial results call—no financials disclosed.

Risk flags

• ●Disclosure risk is high because the announcement omits all financial results, cash position, or operational updates, leaving investors with no basis to assess current performance.
• ●Execution risk remains unaddressed, as claims about the Hemopurifier's capabilities are not supported by clinical data, regulatory progress updates, or commercial milestones.
• ●Regulatory risk persists since the device is described as clinical stage with Breakthrough Device designation, but there is no evidence of FDA approval, market launch, or reimbursement pathway.

Bottom line

This announcement is a routine scheduling notice with no disclosed financials or operational progress. Investors receive only logistical details about when results will be released and how to access the call, with no substantive update on business performance or clinical milestones. Claims about the Hemopurifier's potential remain unsubstantiated by data in this release. The absence of financial information or guidance means this communication is not actionable for investment decisions. The most important takeaway is that investors must wait for the actual results release to gain any insight into the company's financial health or clinical progress.

Announcement summary

(NASDAQ:AEMD) Aethlon Medical, Inc. announced that it will issue financial results for its fiscal first quarter ended June 30, 2026, at 4:15 p.m. ET on Thursday, August 13, 2026. Management will host a conference call on Thursday, August 13, 2026, at 4:30 p.m. ET to review financial results and recent corporate developments. The Hemopurifier is a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies. A replay of the call will be available approximately one hour after the end of the call through September 13, 2026. The replay conference ID number is 6711524.

Disagree with this article?